HFG101 / HighField Bio - LARVOL DELTA

Preliminary Study of Efficacy and Duration of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys (ADA 2024) - "and shown as open squares. Even though some time points are missing (TBD), the trend of HbA1c% reduction after a single HFG1 injection is significant."

Clinical • Late-breaking abstract • Diabetes • Metabolic Disorders